A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Part of paid clinical trials in Duarte, California.
- Sponsor
- CRISPR Therapeutics AG
- Study ID
- NCT06208878
- Status
- Enrolling By Invitation
Conditions
- Hematologic Malignancy
- Solid Malignancy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Non Interventional — OTHERSafety and Efficacy Assessment
Study Details
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Key Dates
- Start date
- Nov 22, 2023
- Status verified
- Aug 2025
- Primary completion
- Aug 31, 2038
- Completion
- Aug 31, 2038
Study Design
- Enrollment
- 70 participants (estimated)
Arms
- Arm: Non InterventionalAll subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.
Primary Outcome Measure
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment. [ Time Frame: 15 years ]
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | - |
| Cedars Sinai | Los Angeles | California | 90048 | - |
| Stanford | Stanford | California | 94305 | - |
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | - |
| Emory | Atlanta | Georgia | 30322 | - |
| University of Chicago | Chicago | Illinois | 60637 | - |
| University of Kansas | Westwood | Kansas | 66205 | - |
| University of Minnesota | Minneapolis | Minnesota | 55455 | - |
| Washington University Saint Louis | St Louis | Missouri | 63110 | - |
| MSKCC | New York | New York | 10065 | - |
| Montefiore Medical Center | The Bronx | New York | 10467 | - |
| Oregon Health and Science University | Portland | Oregon | 97239 | - |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | - |
| UT Southwestern | Dallas | Texas | 75390 | - |
| MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| Methodist Hospital-Sarah Cannon | San Antonio | Texas | 78229 | - |
| University of Utah-Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | - |
Find similar trials in Duarte, CA
Related Studies
- Long-Term Follow-up StudyEnrolling By Invitation · Caribou Biosciences, Inc. · Birmingham, Alabama
- Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical TransplantationRecruiting · Northside Hospital, Inc. · Atlanta, Georgia
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesPHASE1 · Recruiting · Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California
- Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas